LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Authors: Shukui Qin, Masashi Kudo, T Meyer, RS Finn, Peter Vogel, Yibing Bai, Y. Guo, Zhefeng Meng, T. Zhang, Takeshi Satoh, A. Hiraoka, Donatella Marino, Éric Assenat, Lucjan Wyrwicz, Miriam Campos, K. Hsing-Tao, F. Boisserie, Shuang Li, Y. Chen, Andrew X. Zhu - Annals of Oncology 2022 cited by 66